Abeona Therapeutics Inc. (ABEO): Todd Wider , director of Abeona Therapeutics Inc. purchased 5,000 shares on Sep 20, 2016. The Insider buying transaction was reported by the company on Sep 28, 2016 to the Securities and Exchange Commission. The shares were purchased at $5.48 per share for a total value of $27,400.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Aug 3, 2015, Todd Wider (director) purchased 20,000 shares at $5.50 per share price.On Aug 3, 2015, Mark J Ahn (director) purchased 18,182 shares at $5.50 per share price.
Shares of Abeona Therapeutics Inc (ABEO) ended Tuesday, Sep 27, 2016 session in red amid volatile trading. The shares closed down -0.5 points or -8.18% at $5.61 with 5,77,881 shares getting traded. Post opening the session at $6.18, the shares hit an intraday low of $5.46 and an intraday high of $6.18 and the price vacillated in this range throughout the day. The company has a market cap of $188 M and the number of outstanding shares has been calculated to be 3,35,45,703 shares. The 52-week high of Abeona Therapeutics Inc is $6.8 and the 52-week low is $2.05.
Abeona Therapeutics Inc. develops and delivers gene therapy and plasma-based products for rare diseases. The Companys programs include AB0-101 (AAV9 NAGLU) and ABO-102 (scAAV9 SGSH) adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA). It is developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV LK19 FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition the Company is also developing rare plasma protein therapies including SDF Alpha (alpha-1 protease inhibitor) for inherited COPD using its SDF (Salt Diafiltration) ethanol-free process.